Lv1
4 积分 2023-02-01 加入
Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study
1个月前
已完结
Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data
1个月前
已完结
A phase 2 study of the MEK1/2 inhibitor luvometinib in patients with extracranial arteriovenous malformations
1个月前
已完结
Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas
6个月前
已完结
Unstuck and on target! for children with neurofibromatosis type 1: a feasibility and acceptability study
6个月前
已完结
Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas
6个月前
已关闭
A national modified Delphi consensus on the referral and management of NF1 plexiform neurofibroma
6个月前
已完结
Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas
6个月前
已关闭
Recent Advancement of Neurofibromatosis Type 1: A Narrative Review
6个月前
已完结
Luvometinib: First Approval
6个月前
已完结
皖公网安备34019202002308
